SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-24-019976
Filing Date
2024-05-15
Accepted
2024-05-15 17:01:08
Documents
66
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 1241801
2 ex4-1.htm EX-4.1 31288
3 ex31-1.htm EX-31.1 18840
4 ex31-2.htm EX-31.2 18845
5 ex32-1.htm EX-32.1 7483
6 ex32-2.htm EX-32.2 7456
  Complete submission text file 0001493152-24-019976.txt   7123306

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE mymd-20240331.xsd EX-101.SCH 56646
8 XBRL CALCULATION FILE mymd-20240331_cal.xml EX-101.CAL 51568
9 XBRL DEFINITION FILE mymd-20240331_def.xml EX-101.DEF 268113
10 XBRL LABEL FILE mymd-20240331_lab.xml EX-101.LAB 471902
11 XBRL PRESENTATION FILE mymd-20240331_pre.xml EX-101.PRE 365235
70 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 1136284
Mailing Address 855 N. WOLFE STREET SUITE 601 BALTIMORE MD 21205
Business Address 855 N. WOLFE STREET SUITE 601 BALTIMORE MD 21205 856-848-8698
MyMD Pharmaceuticals, Inc. (Filer) CIK: 0001321834 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36268 | Film No.: 24952326
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)